Financial & competing interests disclosure
The author has financial involvement with Vaxine Pty Ltd., an Australian vaccine development company with proprietary interests in adjuvant technologies that may compete with adjuvants mentioned in this article. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.